Insomnia Treatment Guidelines

Introduction to Insomnia Treatment

The American Academy of Sleep Medicine explicitly recommends doxepin (3-6 mg) for sleep maintenance insomnia while specifically recommending against trazodone for any type of insomnia 1, 2

Doxepin demonstrates clinically significant improvements in sleep maintenance parameters, including Wake After Sleep Onset (WASO) reduction by 22-23 minutes, Total Sleep Time (TST) increase by 26-32 minutes, and Sleep Efficiency (SE) improvement by 6.78-7.06% 3, 4, 5
The American Academy of Sleep Medicine task force judged that harms potentially outweigh benefits for trazodone 2
Trazodone failed to achieve clinically significant improvements in any sleep parameter in the single trial meeting inclusion criteria 2

Minimal adverse effects at low doses (3-6 mg) of doxepin, with only mild increase in somnolence at 6 mg (+0.04 risk difference) 3, 4
The American Geriatrics Society recommends avoiding trazodone in elderly patients due to limited efficacy evidence 6

First-line treatment for sleep maintenance insomnia: Doxepin 3 mg taken 30 minutes before bedtime on an empty stomach 7
If inadequate response after 1-2 weeks: Increase to doxepin 6 mg 7
Doxepin 3-6 mg is the preferred first-line pharmacological option for sleep maintenance insomnia in elderly adults 6, 7

The American Academy of Sleep Medicine recommends considering alternative agents such as ramelteon or zaleplon for pure sleep onset problems 1
Doxepin has minimal efficacy for sleep onset issues (sleep latency reduction of only 2-5 minutes) 3, 4

The American Academy of Sleep Medicine recommends doxepin 6mg for sleep maintenance insomnia in elderly patients, including those with dementia, with demonstrated efficacy in improving wake after sleep onset and total sleep time while maintaining a favorable safety profile 8, 9
Doxepin 6mg demonstrates clinically meaningful improvements in sleep maintenance parameters, including a reduction of 22-23 minutes in Wake After Sleep Onset (WASO) and an increase of 26-32 minutes in Total Sleep Time (TST) 8, 9
The 6mg dose maintains an excellent safety profile with minimal adverse effects, including a mild increase in somnolence with a risk difference of only +0.04 compared to placebo 8, 9

An initial trial of 4-6 weeks is recommended to assess efficacy, with maintenance treatment attempted to taper within 3-6 months to determine the lowest effective maintenance dose 8, 10

In adults aged ≥ 65 years, low‑dose doxepin (3 mg) produces clinically significant improvements in sleep maintenance, reducing wake after sleep onset by approximately 22–23 minutes, increasing total sleep time by 26–32 minutes, and enhancing sleep efficiency by ≈ 7 % while showing minimal adverse effects. American Academy of Sleep Medicine recommendation. 11

The American Academy of Sleep Medicine advises against the use of trazodone for insomnia in older adults because it yields only modest reductions in sleep latency (≈ 10 minutes) and wake after sleep onset (≈ 8 minutes), while adverse events occur in roughly 75 % of this population, making potential harms outweigh benefits. 12
Extending a trazodone bridge beyond 7 days increases the risk of adverse events without delivering clinically meaningful sleep improvement; therefore, a 7‑day limit is recommended. American Academy of Sleep Medicine guidance. [12][11]

At a 3 mg dose, doxepin is associated with a very small increase in mild somnolence (risk difference + 0.01 versus placebo); other side‑effects such as headache or diarrhea occur at rates indistinguishable from placebo. American Academy of Sleep Medicine evidence. 11
Low‑dose doxepin (3–6 mg) has not been shown to raise fall risk in elderly patients, supporting its safety for this age group. American Academy of Sleep Medicine data. 11

Adding Cognitive Behavioral Therapy for Insomnia (CBT‑I) alongside pharmacotherapy provides superior long‑term outcomes and facilitates eventual medication discontinuation in older adults. American Academy of Sleep Medicine recommendation. 12

Benzodiazepines and over‑the‑counter antihistamines should be avoided as adjuncts to doxepin in patients aged ≥ 65 years because they carry unacceptable risks of dependency, falls, cognitive impairment, and anticholinergic toxicity. American College of Physicians guidance. 13